SLC30A7 Antibody

Introduction to SLC30A7 Antibodies

SLC30A7 antibodies are immunological reagents specifically designed to detect and bind to the SLC30A7 protein (also known as ZnT7), which functions as a zinc transporter in mammalian cells. These antibodies serve as essential tools for researchers investigating zinc homeostasis mechanisms and related pathological conditions. The target protein, SLC30A7, facilitates zinc transport from the cytoplasm into the Golgi apparatus, playing a crucial role in regulating cellular zinc homeostasis .

The antibodies against SLC30A7 are available in various formats, including unconjugated forms and those conjugated with detection molecules such as horseradish peroxidase (HRP), fluorescein isothiocyanate (FITC), and biotin. These diverse formats enable researchers to employ different experimental approaches when studying SLC30A7 expression, localization, and function in biological systems .

Most commercially available SLC30A7 antibodies are raised in rabbits and demonstrate reactivity with human, mouse, and rat samples, making them versatile tools for comparative studies across different mammalian models. The specificity and sensitivity of these antibodies have been validated through various techniques, including Western blotting, immunohistochemistry, and immunofluorescence .

Antibody Types and Properties

SLC30A7 antibodies are predominantly developed as polyclonal antibodies in rabbit hosts. This polyclonal nature enables recognition of multiple epitopes on the SLC30A7 protein, enhancing sensitivity for detecting endogenous levels of the target protein. Most commercially available antibodies target specific regions of the SLC30A7 protein, such as the N-terminal domain or other distinctive epitopes .

The molecular weight of the SLC30A7 protein is approximately 42 kDa, and antibodies against this protein are typically validated to detect this specific molecular weight in Western blot applications. The antibodies are generally purified using affinity chromatography methods, including peptide affinity and antigen affinity purification, which enhance their specificity for the target protein .

Most SLC30A7 antibodies are provided in liquid format, often suspended in phosphate-buffered saline (PBS) with preservatives such as sodium azide and stabilizers like glycerol. The concentration of these antibodies typically ranges from 1 mg/mL to custom concentrations depending on the manufacturer and specific product formulation .

Target Protein Information

The SLC30A7 gene (HGNC: 19306, OMIM: 611149) encodes a member of the solute carrier family 30, which functions as a zinc transporter. The protein is also known by alternative names including ZnT7 and zinc transporter-like 2 (ZnTL2). The human SLC30A7 gene is mapped to a specific chromosomal location, and its expression has been detected in various tissues .

SLC30A7 exhibits structural characteristics typical of zinc transporters, containing multiple transmembrane domains that facilitate zinc ion movement across cellular membranes. The protein plays a critical role in maintaining zinc homeostasis, which is essential for numerous biological processes including enzyme function, protein synthesis, and immune responses .

Validated Applications

SLC30A7 antibodies have been validated for multiple experimental applications, with each application requiring specific antibody dilutions for optimal results. The primary applications include Western blotting (WB), immunohistochemistry (IHC), immunocytochemistry/immunofluorescence (ICC/IF), and enzyme-linked immunosorbent assay (ELISA) .

Western blotting applications typically employ dilution ranges of 1:500 to 1:5000, allowing researchers to detect SLC30A7 protein in cell and tissue lysates. For immunohistochemistry, recommended dilutions generally range from 1:20 to 1:500, enabling visualization of SLC30A7 distribution in tissue sections. Similarly, immunocytochemistry applications utilize dilutions between 1:20 and 1:200 for detecting the protein in cultured cells .

These antibodies have demonstrated reliable performance in detecting endogenous levels of SLC30A7 in various experimental contexts, making them valuable tools for both basic research and translational studies investigating zinc transport mechanisms and related disorders .

Species Reactivity and Cross-Reactivity

SLC30A7 antibodies exhibit confirmed reactivity with human, mouse, and rat samples, making them suitable for comparative studies across these mammalian species. Some antibodies have additional predicted reactivity with other species, including zebrafish, bovine, horse, sheep, rabbit, dog, chicken, and Xenopus, though these cross-reactivities often require experimental validation .

The cross-species reactivity is based on sequence homology between SLC30A7 proteins in different species. For example, the mouse SLC30A7 displays approximately 87% sequence identity with the human protein, while the rat ortholog shows about 85% sequence identity. This high degree of conservation facilitates the use of the same antibody across multiple species in comparative studies .

Researchers have reported successful use of these antibodies in various experimental models, with published studies confirming their utility in both human cell lines and rodent tissues. This broad species reactivity enhances the versatility of SLC30A7 antibodies in diverse research contexts .

Subcellular Localization and Function

Immunocytochemistry studies using SLC30A7 antibodies have confirmed the predominant localization of this protein to the Golgi apparatus in human cell lines. For instance, staining of A-431 cells with anti-SLC30A7 antibodies reveals a distinct Golgi apparatus pattern, confirming the protein's role in zinc transport within this organelle .

The Golgi localization of SLC30A7 aligns with its functional role in transporting zinc ions from the cytoplasm into the Golgi apparatus. This process is crucial for supplying zinc to zinc-dependent enzymes that function within the secretory pathway and for maintaining appropriate zinc levels in different cellular compartments .

Additionally, immunohistochemistry studies have demonstrated strong positivity for SLC30A7 in the luminal membrane of glandular cells in human small intestine tissue. This observation suggests potential roles for SLC30A7 in zinc absorption or secretion processes in epithelial tissues, beyond its established function in the Golgi apparatus .

Role in Diabetes-Related Conditions

Emerging research has identified significant roles for SLC30A7 in diabetes-related pathologies. Studies indicate that SLC30A7 is involved in the regulation of diabetic cardiomyopathy progression by influencing muco-mitochondrial coupling in hyperglycemic cardiomyocytes. This finding suggests that SLC30A7 may contribute to cardiac complications associated with diabetes .

Furthermore, research has demonstrated that SLC30A7 plays a role in controlling insulin secretion, highlighting its potential importance in glucose homeostasis and diabetes pathophysiology. The precise mechanisms through which SLC30A7 influences insulin secretion remain under investigation, but these findings suggest potential therapeutic implications for targeting SLC30A7 in diabetes management .

Recent studies have also explored the involvement of SLC30A7 in diabetic retinopathy (DR), a common microvascular complication of diabetes. While the specific mechanisms are still being elucidated, preliminary evidence suggests that SLC30A7 may participate in retinal cell responses to hyperglycemic conditions, potentially contributing to DR pathogenesis .

MicroRNA Regulation and Pyroptosis

A significant discovery in SLC30A7 research relates to its regulation by microRNAs, particularly miR-200c-3p. Studies have demonstrated that miR-200c-3p negatively targets SLC30A7 by binding to its 3'-UTR, as confirmed through dual luciferase reporter gene assays. This regulatory relationship appears to influence cellular responses to hyperglycemic conditions .

Importantly, the miR-200c-3p/SLC30A7 axis has been implicated in the regulation of pyroptosis, a form of programmed cell death associated with inflammation, in high glucose-induced human retinal microvascular endothelial cells (HRMECs). Overexpression of miR-200c-3p inhibits SLC30A7 expression and subsequently affects pyroptosis mechanisms in these cells .

These findings suggest that the interaction between miR-200c-3p and SLC30A7 may represent a potential therapeutic target for diabetic retinopathy and possibly other diabetes-related complications. Further research is needed to fully characterize this regulatory pathway and its implications for disease intervention strategies .

Antibody Selection and Optimization

When selecting SLC30A7 antibodies for specific applications, researchers should consider several factors including the antibody's validated applications, species reactivity, and target epitope. For studies focusing on specific domains of SLC30A7, antibodies targeting those regions (such as N-terminal-specific antibodies) may be more appropriate .

Optimization of antibody dilutions is essential for achieving optimal signal-to-noise ratios in different applications. While manufacturers provide recommended dilution ranges, these may require adjustment based on specific experimental conditions, sample types, and detection methods. Preliminary titration experiments are advisable when using these antibodies in new experimental contexts .

For special applications such as co-immunoprecipitation or chromatin immunoprecipitation, additional validation may be necessary to ensure antibody suitability. Some manufacturers provide application-specific protocols that can guide researchers in optimizing experimental conditions for these specialized techniques .